Taken together these published studies demonstrate that while systemically inhibiting the NF‐κB pathways does prevent the development of insulin resistance, it is the myeloid specific inhibition that is the critical cellular target in vivo. This evidence concerns the gene NFKB1 and Insulin resistance.